Thank you for your interest in post-marketing study information. The Post-Marketing Study Registration System on this website has ceased updates as of January 1, 2025, and related information is no longer provided on this platform.

For inquiries about post-marketing studies or related research information, we recommend exploring other resources that provide clinical trial information, such as the Taiwan Clinical Trials (TaiwanClinicalTrials.tw), clinical trial centers at major hospitals, or the website of Center for Drug Evaluation (https://www1.cde.org.tw/ct_taiwan/introduction.html).

We appreciate your understanding and continued support!

Company Name	Title of Study	Update Date
Bristol-Myers Squibb (Taiwan) Ltd.	Empliciti® (elotuzumab) Post-marketing Surveillance Study for Patients with Multiple Myeloma in Taiwan	2024-07-05
Sanofi	Observational study of atopic dermatitis patients treated with dupilumab in Taiwan	2024-07-05
Sanofi	An Observational Study of Enzyme Replacement Therapy-Naïve and Agalsidase beta-Treated Fabry Disease Patients with GLA IVS4+919 G>A Mutation in Taiwan	2024-07-05
Novartis	A Post-Authorization, Multicenter, Multinational, Longitudinal, Observational Safety Registry Study for Patients Treated with Voretigene Neparvovec	2024-05-17
Bayer Taiwan	ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with Larotrectinib / ON-TRK	2024-02-02
Pfizer Ltd. Taiwan	LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES	2024-01-25
Daiichi Sankyo Taiwan Ltd.	A retrospective, non-interventional, multicenter study to estimate the prevalence of HER2-low and describe the standard-of-care, treatment patterns and outcome in real-world practice among unresectable and/or metastatic breast cancer patients with HER2-low status in Taiwan – the RetroBC-HER2L-TW Study.	2024-01-09
Bayer Taiwan Co., Ltd.	AURIGA/An observational study program to investigate the effectiveness of intravitreal Aflibercept in diabetic macular edema and/or macular edema secondary to retinal vein occlusion in a real world setting.	2023-12-12
Novartis (Taiwan) Co., Ltd.	Evaluating the Safety of Myfortic (Mycophenolate sodium) in patients with Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan population	2023-10-30
Janssen, Jahnson & Johnson	Multicenter observational drug registry of Opsumit® (macitentan) in connective tissue disease associated pulmonary arterial hypertension (CTD-PAH) in real world Taiwan clinical setting	2023-10-03